Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 11554049

[Dysmenorrhea].

K Obata·H Hoshiai
View original source ↗Export metadata ↓

Abstract

Dysmenorrhea is commonly observed in women and it reduces their quality of life. Most of dysmenorrhea is based on the disease of endometriosis, uterine myoma, uterine anomalies etc. and some cases are functional. The functional dysmenorrhea arises from the underdevelopment of the uterine growth. There are many different factors for dysmenorrhea in endometriosis, which is the commonest disease with dysmenorrhea, and we have to perform various therapies for pain. Therefore, we discuss in this paper the control for the functional dysmenorrhea and the pain in endometriosis.

Explore related subjects

AnalgesicsCatheter AblationContraceptives, Oral, HormonalCounselingDanazolDenervationDrugs, Chinese HerbalDysmenorrheaEndometriosisFemaleGonadotropin-Releasing HormoneGynecologic Surgical ProceduresHumansLaparoscopyPainPain ManagementParasympatholyticsEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Obata, H Hoshiai. 2001. [Dysmenorrhea].. https://pubmed.ncbi.nlm.nih.gov/11554049/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

[Intramuscular injections in children].

Intramuscular injections are still part of routine care in the treatment of children. Vaccines, premedications and analgesics are administered by this route. The pain associated with an intramuscular injection is severe, the risk of complications is increased, and pharmacodynamics and pharmacokinetics are unpredictable. In many cases, equivalent alternatives of rectal, oral or intranasal routes of administering pharmacologic agents exist. Intramuscular injection of analgesics and premedications to children are-except in case of emergencies-obsolete. This demand corresponds to the guidelines of the World Health Organization (WHO) and the International Association for the Study of Pain (IASP).

Analgesics↗
PubMed2005

[Treatment of extreme tumour pain with morphine and s-ketamine A case report of an 11-year old girl].

We are reporting on the case of an 11-year old girl with a malignant tumour. The extreme pain throughout the body could not be treated by conventional methods. By intravenous application of a morphine and s-ketamine mixture we were able to achieve a very effective analgesic result. Apart from the opiate effect of the morphine the decisive factor was the NMDA-antagonism of the s-ketamine. The latter suppresses central sensitisation and chronic pain and reduces or even prevents the development of opioid tolerance. It was possible to use smaller opiate doses more effectively, thus reducing the side effects of the pain therapy. Under associated whole-body thermochemotherapy the girl experienced general pain relief and we were able to return to conventional therapy with a fentanyl plaster.

Analgesics↗
PubMed2004

Ajulemic acid: A novel cannabinoid produces analgesia without a "high".

A long-standing goal in cannabinoid research has been the discovery of potent synthetic analogs of the natural substances that might be developed as clinically useful drugs. This requires, among other things, that they be free of the psychotropic effects that characterize the recreational use of Cannabis. An important driving force for this goal is the long history of the use of Cannabis as a medicinal agent especially in the treatment of pain and inflammation. While few compounds appear to have these properties, ajulemic acid (AJA), also known as CT-3 and IP-751, is a potential candidate that could achieve this goal. Its chemical structure was derived from that of the major metabolite of Delta9-THC, the principal psychotropic constituent of Cannabis. In preclinical studies it displayed many of the properties of non-steroidal anti-inflammatory drugs (NSAIDs); however, it seems to be free of undesirable side effects. The initial short-term trials in healthy human subjects, as well as in patients with chronic neuropathic pain, demonstrated a complete absence of psychotropic actions. Moreover, it proved to be more effective than placebo in reducing this type of pain as measured by the visual analog scale. Unlike the narcotic analgesics, signs of dependency were not observed after withdrawal of the drug at the end of the one-week treatment period. Data on its mechanism of action are not yet complete; however, the activation of PPAR-gamma, and regulation of eicosanoid and cytokine production, appear to be important for its potential therapeutic effects.

Analgesics↗